CVS stops administering J&J vaccine at pharmacies

CVS Health has stopped offering the Johnson & Johnson COVID-19 vaccine at its pharmacies, though it still will provide the single-dose vaccine at some MinuteClinic retail locations, according to CNBC.

The shot will only be available at roughly 10% of CVS locations. That’s about 1,000 locations in 25 states and Washington D.C. CVS will continue offering vaccines from Pfizer-BioNTech and Moderna, which are more effective that the J&J vaccine and given through two doses.

The change comes as the J&J vaccine has received some pushback and faced challenges since it was given emergency authorization use by the Federal Drug Administration. Distribution of the vaccine was temporarily paused by the CDC in April over fears the shot was linked to rare blood clotting disorders. However, the CDC quickly reversed the pause.  

"We remain committed to helping end this deadly pandemic as quickly as possible,” J&J told CNBC. “A single-shot vaccine that provides protection and prevents hospitalization and death is an important tool in the global fight against COVID-19. Evidence from our Phase 3 ENSEMBLE study demonstrates the efficacy of the J&J single-shot COVID-19 vaccine, including against viral variants that are highly prevalent. Regardless of race and ethnicity, age, geographic location and comorbidities, these results remain consistent."

CVS stated it has made the change over the last several weeks.

See the full story below:

 

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.